Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TRPV4 | Q9HBA0 | 10/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.47 |
| ▸ | ALB | P02768 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29222228 | 0.89 | GSTO1 (0.52) | TSHRKMT2ACNR1ENPP2ALB | |
| SCHEMBL5103723 | 0.87 | CYP19A1 (0.56) | TSHRTRPV4CYP19A1TRPM8CYP3A4 | |
| SCHEMBL24512255 | 0.82 | CNR1 (0.63) | KMT2ACNR1ALDH1A1 | |
| SCHEMBL12424482 | 0.81 | TSHR (0.56) | TSHRTRPV4CYP19A1CYP3A4KCNH2 | |
| SCHEMBL26029337 | 0.81 | TRPV4 (0.43) | KMT2ATRPV4CYP19A1TRPM8CYP3A4 | |
| SCHEMBL26025566 | 0.80 | TRPV4 (0.43) | TRPV4CYP19A1TRPM8CYP3A4KCNH2 | |
| SCHEMBL29717113 | 0.79 | GSTO1 (0.55) | KMT2ATRPV4CNR1ALBALDH1A1 | |
| SCHEMBL29717119 | 0.79 | CNR1 (0.47) | CNR1ALBALDH1A1 | |
| SCHEMBL29222024 | 0.79 | CNR1 (0.47) | CNR1ALBALDH1A1 | |
| SCHEMBL2959205 | 0.79 | TRPV4 (0.50) | TRPV4CYP19A1TRPM8CYP3A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137300-A1 | Indolizine Acetic Acid Derivatives as CRTH2 Antagonists | ARGENTA ORAL THERAPEUTICS LIMITED (GB) | 2010-06-03 | — | — | US | disclosed |
| CN-101678009-A | Indolizine acetic acid derivatives as CRTH2 antagonists | ARGENTA DISCOVERY LTD | 2010-03-24 | — | — | CN | disclosed |
| EP-2136804-A1 | INDOLIZINE ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | Argenta Oral Therapeutics Limited (GB) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008113965-A1 | INDOLIZINE ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137300-A1 | Indolizine Acetic Acid Derivatives as CRTH2 Antagonists | HRH1, HRH4, HRH2 | TSHR 222/4885KMT2A 2303/4885TRPV4 629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.